Binod Dhakal
Overview
Explore the profile of Binod Dhakal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
1300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, et al.
Blood Adv
. 2025 Mar;
PMID: 40088469
No abstract available.
2.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500453.
PMID: 40053892
No abstract available.
3.
Dhakal B, He J, Schecter J, Deraedt W, Slaughter A, Lonardi C, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39966019
Background: Early continuous lenalidomide use for multiple myeloma (MM) treatment has led to more patients with lenalidomide-refractory disease at earlier lines of therapy (LOTs). Real-world treatment practices and outcomes in...
4.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401730.
PMID: 39965175
Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety,...
5.
Costa L, Medvedova E, Dhakal B, Dholaria B, Godby K, Bal S, et al.
Blood Cancer J
. 2025 Feb;
15(1):13.
PMID: 39910064
No abstract available.
6.
Treon S, Kotton C, Park D, Moranzoni G, Lemvigh C, Gathe Jr J, et al.
Front Immunol
. 2025 Feb;
15:1369619.
PMID: 39906744
Background: Cytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)-related respiratory failure. Bruton tyrosine kinase (BTK) is involved in...
7.
Dhakal B, Hari P, Chhabra S, Szabo A, Lum L, Glass D, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39875173
Background: Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo...
8.
Akhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, et al.
Blood Adv
. 2025 Jan;
PMID: 39786391
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of...
9.
Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells
Narra R, Peshin S, Dhakal B
Acta Haematol
. 2024 Dec;
:1-16.
PMID: 39733769
Background: Recent advancements in cellular therapies, particularly chimeric antigen receptor T-cells (CAR-T) and T-cell-engaging bispecific antibodies have significantly altered the therapeutic landscape for multiple myeloma. There are two US FDA...
10.
Yong K, Einsele H, Schecter J, Roccia T, Deraedt W, Lendvai N, et al.
Eur J Cancer
. 2024 Dec;
215:115157.
PMID: 39673835
Background: The introduction of proteasome inhibitors (PIs) and lenalidomide as treatment for newly diagnosed multiple myeloma (MM) has led to an increased population of lenalidomide-refractory patients. Limited data are available...